KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies
暂无分享,去创建一个
P. Greenberg | J. Cortes | I. Lewis | A. Wei | J. Lancet | A. Advani | S. Durrant | G. Yarranton | J. Walling | R. Swords | M. Hertzberg